Last reviewed · How we verify
NCT05939622
Efficacy of the Therapy With BRAINMAX® Using fMRI for the Treatment of Patients With Asthenia After COVID-19
Phase 4 trial testing Structural and functional MRI in Asthenia in 30 participants. Completed in 20 December 2022.
20 December 2022
Quick facts
| Lead sponsor | Promomed, LLC |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 18 May 2022 |
| Primary completion | 20 December 2022 |
| Estimated completion | 20 December 2022 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Structural and functional MRI
- Ethyl methyl hydroxypyridine succinate + Meldonium — full drug profile →
- Placebo
Conditions studied
- Asthenia — all drugs for Asthenia →
- COVID-19 — all drugs for COVID-19 →
- Functional MRI — all drugs for Functional MRI →
- Cognitive Impairment — all drugs for Cognitive Impairment →
Sponsor
Promomed, LLC — full company profile →
Who can join
Adults 25 to 50, any sex, with Asthenia or COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
to assess executive network using resting-state fMRI and patterns of brain activation using task fMRI with a cognitive paradigm, against the background of taking the drug in comparison with placebo in patients with post-COVID asthenic syndrome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05939622
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Asthenia
Currently open trials in the same condition.
- NCT07059871 — A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease. · NA · recruiting
- NCT06898476 — Silkworm Pupa Powder Improves Dementia. · NA · recruiting
Other Promomed, LLC trials
Trials by the same sponsor.
- NCT05722691 — Study for Efficacy and Safety Assessment of the Drug RADAMIN®VIRO for COVID-19 Postexposure Prophylaxis · Phase 3 · completed
- NCT05689827 — Safety and Efficacy of the Therapy With BRAINMAX® for the Treatment of Patients With Asthenia After COVID-19 · Phase 4 · completed
- NCT05656495 — Efficacy and Safety of Ambervin® and Standard Therapy in Hospitalized Patients With COVID-19 · Phase 3 · completed
- NCT05595824 — Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19 · Phase 3 · completed
- NCT05185284 — Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standar · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05939622 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Promomed, LLC
- Last refreshed: 13 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05939622.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing